Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Decitabine-Based Maintenance Therapy in AML in Remission
NCT05010772Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inqovi in acute myeloid leukemia (AML) (5 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events up to 5 years. Started Oct 2021; status: recruiting.
02
Drugs
inqovi
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05010772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05010772.